Clearmind Medicine Marks Milestone in Clinical Trials
Clearmind Medicine Inc., a clinical-stage biotech company, has reached a significant milestone with the completion of patient enrollment for the first cohort of its Phase I/IIa clinical trial that focuses on treating Alcohol Use Disorder (AUD). The trial evaluates CMND-100, a proprietary drug derived from MEAI, reflecting the company's commitment to developing unique solutions for complex health challenges.
Successful Enrollment and Trial Details
Six patients have been successfully enrolled in the trial, with involvement from notable institutions such as Johns Hopkins University School of Medicine and Yale School of Medicine's Department of Psychiatry. This Phase I/IIa trial is structured to assess various critical parameters of CMND-100, including its safety, tolerability, and pharmacokinetic profile.
Additionally, the trial will investigate preliminary efficacy signals, aiming to gauge reductions in alcohol cravings and consumption among both non-treatment-seeking individuals who exhibit heavy binge drinking patterns, and treatment-seeking individuals meeting AUD criteria as per DSM-5 guidelines. For participation, individuals must show an interest in reducing or ceasing alcohol intake.
Dr. Zuloff-Shani's Insights
Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine, emphasized the significance of this enrollment stage, describing it as a key point in the CMND-100 trial. He highlighted the swift progress made in enrolling the last patient within a commendable timeline and expressed optimism that the two additional trial sites in Israel will further enhance enrollment pace.
Dr. Zuloff-Shani also noted the momentum gained from collaborations with prestigious institutions, affirming interest in MEAI-based therapeutics and Clearmind's dedication to addressing the needs of those affected by AUD.
About Clearmind Medicine
Clearmind Medicine is dedicated to exploring and developing psychedelic-derived therapies aimed at alleviating prevalent health problems that remain inadequately addressed. The company focuses on the commercialization of its psychedelic-based compounds as regulated medicines, dietary supplements, or food products.
The firm's intellectual property portfolio is impressive, comprising nineteen patent families and 31 granted patents. Clearmind endeavors to continually expand this portfolio through acquiring additional patents and intellectual property.
Stock Market Information
Investors can find Clearmind’s shares traded on the Nasdaq under the ticker symbol CMND, as well as on the Frankfurt Stock Exchange under CWY0. Ensuring transparent investor relations is paramount for the company, which is reflected in their ongoing engagement initiatives.
Looking Ahead
With clinical trials registered on ClinicalTrials.gov, Clearmind Medicine is poised to make substantial strides in the field of psychedelic therapeutics. The potential for CMND-100 to become a transformative treatment for AUD aligns with the company's mission to pioneer innovative healthcare solutions. As they proceed with trial phases, the anticipation builds for the release of topline data that could usher in a new era of treatment for those grappling with AUD.
Frequently Asked Questions
What is the purpose of Clearmind's clinical trial?
Clearmind's clinical trial aims to evaluate the safety and efficacy of CMND-100 for treating Alcohol Use Disorder.
How many patients are involved in the trial?
Currently, six patients have been enrolled, with the trial designed to test the drug's pharmacokinetic properties and preliminary effectiveness.
Which institutions are participating in the trial?
Notable participating institutions include Johns Hopkins University School of Medicine and Yale School of Medicine's Department of Psychiatry.
What is CMND-100?
CMND-100 is Clearmind's proprietary drug candidate, based on MEAI, aimed at reducing cravings and consumption in individuals with AUD.
Where can I find more information about Clearmind Medicine?
For additional details, you can visit Clearmind Medicine's official website.
